

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Amendments to the Claims:**

Claims 1-20 (canceled)

Claim 21 (new)      An isolated or recombinant binding compound comprising an antigen binding portion from an antibody, which specifically binds to a DAP12 polypeptide comprising the amino acid sequence of SEQ ID NO: 2 or 6.

Claim 22 (new)      The binding compound of claim 21, wherein the antigen binding portion of the antibody is a single chain antibody.

Claim 23 (new)      The binding compound of claim 21, wherein the binding compound is a polyclonal antibody.

Claim 24 (new)      The binding compound of claim 21, wherein the binding compound is a monoclonal antibody.

Claim 25 (new)      The binding compound of claim 21, wherein the binding compound is a humanized antibody.

Claim 26 (new)      The binding compound of claim 21, wherein the binding compound is a chimeric antibody.

Claim 27 (new)      The binding compound of claim 21, wherein the binding compound specifically binds to residues 1-87 of SEQ ID NO: 2 or 6.

Claim 28 (new)      The binding compound of claim 21, wherein the binding compound specifically binds to residues 2-87 of SEQ 2 or 6.

Claim 29 (new)      The binding compound of claim 21, wherein the binding compound has a  $K_d$  of at least 30  $\mu$ M.

Claim 30 (new)      The binding compound of claim 21, wherein the binding compound has a  $K_d$  of at least 30 mM.

Claim 31 (new)      The binding compound of claim 21, wherein the binding compound has a  $K_d$  of at least 30 pM.

Claim 32 (new)      The binding compound of claim 21, wherein the binding compound is detectably labeled.

Claim 33 (new)      The binding compound of claim 32, wherein the detectable label is selected from the group consisting of a radioactive label and a fluorescent label.

Claim 34 (new)      The binding compound of claim 21, wherein the binding compound is coupled to a toxin or a radionuclide.

Claim 35 (new)      The binding compound of claim 21, wherein the binding compound specifically binds to the polypeptide of SEQ ID NO: 2 or 6 in association with CD94/NKG2C.

Claim 36 (new)      The binding compound of claim 21, wherein the binding compound specifically binds to the polypeptide of SEQ ID NO: 2 or 6 in association with MDL-1.

Claim 37 (new)      A kit comprising the binding compound of claim 21 and:  
a) a compartment comprising the binding compound; and  
b) instructions for use or disposal of reagents in the kit.

Claim 38 (new)      A composition comprising the binding compound of claim 21 and a pharmaceutically acceptable carrier.